Medical Product
Communications That Are Consistent With the Food and Drug
Administration Required Labeling -Questions and Answers
Extension without change of a currently approved collection
No
Regular
07/29/2021
Requested
Previously Approved
36 Months From Approved
08/31/2021
9,720
9,720
38,880
38,880
0
0
This information collection supports
agency guidance. The guidance provides third-party disclosure
recommendations firms should include in their drug and device
labeling and prescription drug and restricted device advertising
that contain information not found in the FDA-required labeling for
their medical products but that are “consistent with the
FDA-required labeling” (as that term is explained in the guidance)
if they choose to publicly disseminate such materials.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.